LLY
Eli Lilly & Co.
stock NYSE

Dependence for life and it has a subscription fee? Why don't I own LLY?

A steady schedule is good IF there is something on a dip you can't pass up then you can go bulk. Like a month ago Eli Lilly dropped to $880 on fake news I went in as heavy as I could because i know LLY is the top big pharma company & that $1200 month end is not crazy. Right now it's at 1160

Because LLY is just better when it comes to GLPs. Market is pricing them as completely inferior

Buy LLY?

LLY

PROFILE
\- Location: Hungary (Budapest)
\- My age: 32
\- Account: TBSZ — 0% CGT after 5 years
\- Broker: Interactive Brokers (IBKR)
\- Monthly: 500,000 HUF (\~€1,324/month)
\- Total deployed over 10 years: \~€159,000
\- Horizon: 10 years
\- Risk: High
\---
PORTFOLIO — 8 positions, near-zero overlap
ETFs (all accumulating, Ireland domicile):
• CNDX · iShares Nasdaq 100 UCITS · Xetra · 35%
• EXUS · Xtrackers MSCI World ex-USA · Xetra · 18%
• WQTM · WisdomTree Quantum Computing · Xetra · 8%
• CSKR · iShares MSCI Korea · LSE · 5%
• BTC1 · Bitwise Core Bitcoin ETP · Xetra · 5%
Direct stocks:
• TSM · TSMC · NYSE · 15%
• LLY · Eli Lilly · NYSE · 8%
• NOW · ServiceNow · NYSE · 5%
\---
LOGIC
CNDX covers my full US mega-cap tech list in one
accumulating UCITS wrapper. No estate tax risk.
No dividends.
EXUS covers developed world ex-US. Zero overlap
with CNDX by index design — US companies
excluded entirely.
TSMC is my highest conviction single stock.
Makes chips for every company inside CNDX.
WQTM is quantum optionality sized at 8% —
survivable if it fails, transformative if
quantum delivers commercially by 2031.
LLY is my only non-tech position. Near-zero
correlation to tech drawdowns.
CSKR is Samsung + SK Hynix at 45% of the fund.
They supply HBM memory inside every Nvidia GPU.
Korea is classified as Emerging Market by MSCI
so zero overlap with EXUS (developed only).
NOW is enterprise AI automation. 98% gross
retention, 20%+ revenue growth annually.
BTC1 is pure speculation at 5%. Cheapest Bitcoin
ETP in Europe at 0.05% TER until end 2026.
\---
OVERLAP:
Ran a full overlap check across all 8 positions.
Total duplicated capital: under 1.1% of portfolio.
CNDX and EXUS have zero overlap by design.
CSKR has zero overlap with both ETFs.
Questions:
Does this look solid? Any overlap I missed?
Any position you would swap or remove?
All honest feedback welcome.